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TonEBP suppresses adipogenesis 
and insulin sensitivity by blocking 
epigenetic transition of PPARγ2
Jun Ho Lee, Hwan Hee Lee, Byeong Jin Ye, Whaseon Lee-Kwon, Soo Youn Choi & 
Hyug Moo Kwon
TonEBP is a key transcription factor in cellular adaptation to hypertonic stress, and also in 
macrophage activation. Since TonEBP is involved in inflammatory diseases such as rheumatoid 
arthritis and atherosclerosis, we asked whether TonEBP played a role in adipogenesis and insulin 
resistance. Here we report that TonEBP suppresses adipogenesis and insulin signaling by inhibiting 
expression of the key transcription factor PPARγ 2. TonEBP binds to the PPARγ 2 promoter and 
blocks the epigenetic transition of the locus which is required for the activation of the promoter. 
When TonEBP expression is reduced, the epigenetic transition and PPARγ 2 expression are markedly 
increased leading to enhanced adipogenesis and insulin response while inflammation is reduced. 
Thus, TonEBP is an independent determinant of adipose insulin sensitivity and inflammation. TonEBP 
is an attractive therapeutic target for insulin resistance in lieu of PPARγ agonists.
Tonicity-responsive enhancer binding protein (TonEBP), also known as nuclear factor of activated T 
cells 5 (NFAT5), belongs to the Rel family of transcription factors along with nuclear factor κ B (NFκ B) 
and NFAT1 to NFAT41,2. Members of this family share the Rel-homology domain of ~250 amino acids 
involved in DNA binding. TonEBP was originally identified as the central regulator of transcriptional 
response to hypertonic stress1,3–5. Recent studies have revealed that TonEBP is also involved in the 
pro-inflammatory activation of macrophages by promoting expression a host of pro-inflammatory genes 
in response to Toll-like receptor 4 activation6, as well as by stimulating the activity of NFκ B7,8. Genetic 
haploinsufficiency of TonEBP is associated with reduced inflammation leading to nearly complete pre-
vention of rheumatoid arthritis and atherosclerosis in mouse models9,10. Thus, relatively moderate reduc-
tion in TonEBP expression results in surprisingly dramatic suppression of inflammatory diseases making 
TonEBP an attractive therapeutic target.
Adipose tissues play a central role in energy homeostasis11–13. Under conditions of excess caloric 
intake, expansion of adipose tissue is a healthy way of storing excess lipid because excess lipid deposition 
in cells other than adipocytes causes lipotoxic side effects14–16. Adipose inflammation is involved in var-
ious aspects of the adipose tissue expansion. On one hand, adipocyte inflammation is required for adi-
pogenesis and healthy adipose tissue expansion. Adipocyte-specific reduction in inflammation results in 
reduced adipogenesis and limited adipose tissue expansion in combination with increased ectopic lipid 
accumulation in response to excess caloric intake17. On the other hand, obesity is often associated with 
higher number of pro-inflammatory macrophages within the adipose tissue leading to chronic adipose 
inflammation and insulin resistance18–23.
Given the role of TonEBP in various inflammatory diseases, our long-term goal is to determine the 
function of TonEBP in adipose tissue expansion and insulin resistance. We began the quest by examining 
the role of TonEBP in adipogenesis and adipocyte inflammation. Here we report that TonEBP suppresses 
the epigenomic transition of the peroxisome proliferator-activated receptor gamma 2(PPARγ 2) promoter 
and adipogenesis while promoting adipocyte inflammation.
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Results
TonEBP suppresses adipocyte differentiation in association with PPARγ downregulation. To 
understand the function of TonEBP in adipocyte differentiation, we first examined TonEBP expression at 
several time points during adipocyte differentiation. 3T3-L1 cells were switched to adipogenesis inducing 
medium (AIM) for up to 8 days. Adipogensis was evident as indicated by pronounced expression of 
peroxisome proliferator-activated receptor γ (PPARγ - both PPARγ 1 and PPARγ 2 are shown as double 
bands), fatty acid binding protein 4 (FABP4), and perilipin (Fig. 1a), and accumulation of triglycerides 
(Fig. 1b). During this period, TonEBP levels decreased markedly compared to non-differentiating cells, 
i.e., those cells kept in growth medium (GM) (Fig. 1a). The decrease was evident on day 2 and continued 
up to day 8.
We investigated how adipocyte differentiation was affected after manipulating TonEBP expression. First, 
we examined the effects of TonEBP over-expression using adenovirus in 3T3-L1 cells. Over-expression 
of TonEBP followed by switch to AIM resulted in a decreased accumulation of triglycerides and reduced 
expression of PPARγ ’s (see Supplementary Fig. S1), indicating that adipocyte differentiation was blunted. 
Reversely, knock-down of TonEBP using siRNA before switching to AIM resulted in an increased accu-
mulation of triglycerides (Fig. 1b).
We further examined the effect of TonEBP using pre-adipocytes obtained from the stromal vascular 
fractions of mouse subcutaneous fat fads as described in Methods. We explored the TonEBP+/Δ mice 
(heterozygotes) because they display TonEBP haplo-deficiency5. As expected, differentiated adipocytes 
from the TonEBP+/Δ mice showed reduced TonEBP expression compared to those from TonEBP+/+ lit-
termates (Fig. 1c). The TonEBP+/Δ cells showed elevated expression of PPARγ ’s (Fig. 1c) and higher tri-
glyceride content (Fig. 1d) consistent with the suppressive effects of TonEBP on adipocyte differentiation.
Expression of PPARγ ’s increased both on 1.5 and 6 days in AIM after TonEBP knockdown, which 
responded to rosiglitazone treatment by further enhancing their expression along with adipogenic pro-
teins such as FABP4 and perilipin (Fig.  2a). The increases in protein expression were associated with 
parallel increase in their mRNA’s as well as mRNA’s for other adipogenic genes - stearoyl-CoA desaturase 
1 (SCD1), sterol regulatory element-binding protein 1c (SREBP1c), and glucose transporter 4 (glut4) 
(Fig.  2b and c) - demonstrating that stimulation of transcription was involved in the process. Since 
PPARγ is a key transcription factor involved in the upregulation of adipogenic genes24 and expression 
Figure 1. TonEBP expression decreases during adipogenesis, and knockdown or genetic deficiency of 
TonEBP expression enhances adipocyte differentiation (a) 3T3-L1 cells were cultured in growth medium 
(GM) or adipogenesis inducing medium (AIM) for up to 8 days as indicated and immunoblotted for 
various proteins named on the left. (b) Cells were transfected with TonEBP-targeted siRNA or scrambled 
(Scr) siRNA followed by culture in GM or AIM for 6 days, and stained with Oil-Red-O and the stain was 
extracted and measured to assess intracellular TG. Mean + SD, n= 4. (c and d) Stromal vascular fractions 
were isolated from subcutaneous fat pads of TonEBP+/Δ mice and their TonEBP+/+ littermates, and cultured 
for 5 days in modified AIM. Immunblots (c) and TG contents (d) are shown. Mean + SD, n = 3. *p < 0.05.
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of CCAAT-enhancer-binding protein β (C/EBPβ ) was not affected in response to TonEBP knockdown 
(Fig. 2a), we examined PPARγ further. Transcriptional activity of PPARγ measured by a PPAR-responsive 
element reporter was enhanced by TonEBP knockdown as well as by rosiglitazone (see Supplementary 
Fig. S2). In addition, the PPARγ proteins induced by TonEBP were found mostly in the nucleus (see 
Supplementary Fig. S2) further demonstrating that they were transcriptionally active. Enhanced expres-
sion of PPARγ by TonEBP knockdown and rosiglitazone treatment synergistically stimulated adipogenic 
and lipogenic expression. These data suggest that TonEBP suppress adipogenesis by way of reducing 
PPARγ expression.
During adipose tissue expansion caused by calorie overload, adipogenesis is stimulated by hypertro-
phied adipocytes leading to adipocyte hyperplasia25. The bone marrow-derived mesenchymal stem cell 
can be committed into adipogenic fate and it is the critical step for adipogenesis in vivo25. We asked 
whether TonEBP had suppressive effects on adipogenesis in human bone marrow-derived mesenchymal 
stem cells. Consistent with other data here, TonEBP knockdown promoted the adipogenic commitment 
Figure 2. Enhanced expression of adipogenic proteins and genes in response to TonEBP knockdown. (a) 
3T3-L1 cells were transfected with scrambled or TonEBP-targeted siRNA followed by culture in GM or AIM 
for 1.5 or 6 days. Where indicated, 1 μ M rosiglitazone (Rosi) was added. Immunoblotting was performed 
as in Fig. 1. (b) Cells transfected with scrambled (open bars) and TonEBP-targeted siRNA (filled bars) were 
cultured in AIM for up to 6 days as indicated. Quantitative PCR was performed for mRNA for TonEBP and 
adipogenic genes and expressed in fold over 0 day. (c) Cells transfected with siRNA were cultured for 6 days 
in GM or AIM without or with rosiglitazone. Quantitative RT-PCR was performed for adipogenic genes and 
Glut4. Mean + SD, n = 4. *p < 0.05.
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of these cells (see Supplementary Fig. S3) further supporting the role of TonEBP in the adipogenesis 
under physiological conditions.
TonEBP suppresses insulin signaling in adipocytes. Adipocyte differentiation is accompanied by 
enhanced capability to transport glucose and lipid into the cells13,17,25. As adipocytes are central regu-
lator of glucose and lipid homeostasis, their insulin responsiveness is critical21–23. We asked whether 
TonEBP affected insulin signaling in adipocytes. First, we examined insulin-responsive AKT phospho-
rylation at serine 473. We explored adipocytes obtained from animals from the TonEBP haplo-deficient, 
TonEBP+/Δ mice. Again, adipocytes from the heterozygotes displayed reduced TonEBP expression, and 
enhanced PPARγ 2 expression, compared to adipocytes from their TonEBP+/+ littermates (Fig. 3a). More 
importantly, insulin-stimulated AKT phosphorylation was > 70% higher in TonEBP+/Δ adipocytes com-
pared to TonEBP+/+ adipocytes. Also, in 3T3-L1 cells whose TonEBP had been knocked down before 
they were induced to differentiate into adipocytes, insulin-stimulated AKT phosphorylation was elevated 
(Fig. 3b) indicating enhanced insulin signaling. This observation demonstrates that variations in the level 
of TonEBP expression negatively influence insulin signaling in adipocytes.
We next analyzed insulin-stimulated glucose uptake in differentiated 3T3-L1 cells. Initial rate of 
glucose uptake was measured using a nonhydrolyzable fluorescent glucose named 6-(N-(7-nitrobenz-
2-oxa-1,3-diazol-4-yl)amino)-6-deoxyglucose (6-NBDG). As shown in Fig.  3c, insulin-stimulated glu-
cose uptake was significantly elevated in those cells whose TonEBP had been knocked down regardless 
of the absence or presence of rosiglitazone. The elevated glucose uptake is consistent with increased 
Glut4 mRNA observed in these cells (Fig.  2c). In sum, TonEBP suppresses insulin signaling in adipo-
cytes in such a way that lower TonEBP expression is associated with elevated glucose uptake and AKT 
phosphorylation.
TonEBP suppresses the PPARγ2 promoter by blocking epigenetic activation. The process 
of adipocyte differentiation involves a complex network of transcription factors leading to expres-
sion of the master regulator PPARγ . AIM contains insulin which promotes expression of SREBP1c, 
3-isobutyl-1-methylxanthine (IBMX) which activates cAMP-responsive element-binding protein (CREB) 
via elevating cellular cAMP concentrations, and dexamethasone which promotes CCAAT-enhancer-binding 
protein δ (C/EBPδ ) expression via activation of glucocorticoid receptor. All of these transcription factors 
are involved in the transcriptional stimulation of the PPARγ gene.
In order to understand how TonEBP suppressed adipogenesis, we examined the effects of deleting 
individual AIM components. Deleting insulin, IBMX, or dexamethasone dramatically reduced adipo-
genesis based on cellular accumulation of triglycerides (see Supplementary Fig. S4) and mRNA levels 
of PPARγ and FABP4 (see Supplementary Fig. S4). On the other hand, the stimulation by TonEBP 
knockdown was maintained in every case indicating that TonEBP action was largely independent of 
these factors. Since PPARγ mRNA was elevated in response to TonEBP knockdown, we asked whether 
TonEBP directly suppressed the PPARγ promoter.
PPARγ 2, which is the upper band of the doublet shown in Fig. 1a26, is the predominant form of PPARγ 
expressed in adipocytes26 as shown in (Fig. 3a). A critical early step in adipogenesis is the activation of 
the PPARγ 2 promoter. This is initiated by epigenetic transition in which de-methylation of Histone H3 
allows chromatin opening leading to the initial recruitment of C/EBPβ27–29. We asked whether TonEBP 
played a role in the epigenetic transition. We started by examining TonEBP interaction to the promoter 
region even though we did not find potential TonEBP DNA binding sites. Using DNA affinity precipita-
tion assay (DAPA) using a probe covering the proximal 0.5 kb upstream the PPARγ 2 gene, we observed 
a strong TonEBP binding in undifferentiated cells, i.e., 3T3-L1 cells in GM (Fig.  4a). 18 h after switch 
to AIM, the binding decreased dramatically coincident with the chromatin remodeling30. This dissocia-
tion of TonEBP from the promoter took place without significant decrease in TonEBP expression level 
suggesting that the dissociation was regulated at a post-translational level. The TonEBP binding was 
confirmed by chromatin immunoprecipitation (ChIP) analyses (Fig.  4b). The ChIP data also revealed 
that the binding was limited within 360 bp upstream of the gene as little binding was observed upstream, 
for example 1016 to 787 bp upstream. Next, we examined chromatin opening of the proximal promoter 
region by analyzing sensitivity to micrococcal nuclease to calculate chromatin accessibility as described 
in Fig.  4c. Chromatin accessibility increased in 12 h after switch to AIM which was maintained up to 
48 h. This “chromatin opening” was associated with reduced di-methylation of lysine 9 in Histone H3 and 
increased C/EBPβ binding (Fig.  4d, open bars). Interestingly, chromatin accessibility was dramatically 
higher in those cells whose TonEBP had been knocked down in association with further decrease in the 
di-methylation of Histone H3 and potent increase in the C/EBPβ binding. Taken together, the data in 
Fig. 4 demonstrate that TonEBP binding to the proximal region of the PPARγ 2 promoter is associated 
with Histone H3 di-methylation and prevention of C/EBPβ binding. The bound TonEBP dissociates from 
the promoter at early stages of adipogenesis. Knockdown of TonEBP enhances de-methylation of Histone 
H3, chromatin accessibility and C/EBPβ binding.
We cloned fragments of mouse genomic DNA covering nucleotide position − 3023 to + 168 relative to 
the transcription start site of PPARγ 2, − 1069 to + 168, and− 530 to + 168 as shown in Fig. 5a. These DNA 
fragments were individually cloned upstream of a promoter-less luciferase reporter (pGL3). Cells trans-
fected with the longest reporter (PPARγ 3 kb promoter) displayed luciferase activity in a dose-dependent 
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manner (Fig. 5b). Interestingly, the promoter activity was stimulated by TonEBP knockdown in all three 
constructs (Fig. 5c) indicating that TonEBP-responsive transcriptional suppression was localized within 
0.5 kb upstream of the transcription start site. C/EBPα is one of the transcription factors recruited to the 
PPARγ 2 promoter subsequent to the initial binding of C/EBPβ26,27. C/EBPα expression was enhanced 
in response to TonEBP knockdown (Fig.  2) most likely as a result of the increased expression PPARγ 
which stimulates the C/EBPα promoter26,27. Since there is a C/EBP binding site in the proximal region 
of the PPARγ 2 promoter, we measured C/EBP activity and found that it was increased in response 
Figure 3. Enhanced insulin response in TonEBP deficiency. (a) Primary adipocytes were isolated from 
epididymal fat pads of TonEBP+/Δ mice and their TonEBP+/+ littermates. Some of the adipocytes were treated 
with insulin as indicated before they were immunoblotted for AKT and p-AKT, as well as TonEBP and 
PPARγ . The ratio of p-AKT/AKT is shown in Mean + SD, n = 3. (b) 3T3-L1 transfected with scrambled 
or TonEBP-targeted siRNA were cultured in AIM. After serum starvation, the cells were treated without 
(0 min) or with insulin for up to 30 min as indicated, followed by immunoblotting for AKT and p-AKT. (c) 
Cells transfected with siRNA’s were cultured for 5 days in GM or AIM without or with rosiglitazone. The 
cells were serum-starved before a 30 min uptake of 6-NBDG in the absence or presence 100 nM insulin 
was measured. The ratio of uptake in the presence of insulin over the absence is shown Mean + SD, n = 3. 
*p < 0.05.
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to TonEBP knockdown (Fig.  5d). As expected, the stimulation of the PPARγ 2 promoter construct by 
TonEBP knockdown was dependent on the C/EBP binding site (Fig. 5e).
The data in Figs. 4 and 5 demonstrate two sites of TonEBP action in the suppression of the PPARγ 2 
promoter – epigenetic suppression of the locus by direct binding, and indirect inhibition of C/EBPα 
expression via suppression of PPARγ 2 expression. The major site is clearly the epigenetic suppression of 
the promoter locus by way of Histone H3 methylation. When TonEBP expression is lowered, the epige-
netic opening of the promoter in response to adipogenic signal is greatly enhanced.
Reduced pro-inflammatory cytokine expression in response to TonEBP knockdown despite 
the increased adipogenesis. One of the main features of adipogenesis is the upregulation of 
pro-inflammatory cytokines31. In visceral fats, adipocyte inflammation is required for healthy adipose tis-
sue expansion and remodeling during calorie overload17. On the other hand, chronic adipose tissue inflam-
mation drives insulin resistance18–23. In macrophages, TonEBP promotes expression of pro-inflammatory 
genes by directly binding to their promoters6. We examined expression of inflammation-related genes in 
adipocytes differentiated from 3T3-L1 cells. As expected from the elevated PPARγ expression, adiponec-
tin mRNA increased in response to TonEBP knockdown (Fig. 6a). On the other hand, mRNA levels of 
a host of pro-inflammatory genes – TNFα , IL-1β, IL-6, leptin, and resistin – decreased in response to 
TonEBP knockdown. In addition, expression and secretion of monocyte chemotactic protein-1 (MCP-1), 
Figure 4. TonEBP binds to the PPARγ2 promoter, and blocks histone methylation and chromatin 
accessibility. (a) 3T3-L1 cells were cultured in GM or AIM for 18 h, and then, DNA affinity precipitation 
assay (DAPA) was performed with probes containing sequence of 0.5 kb PPARγ 2 promoter (see 
Fig. 6a). The whole lysates and the DAPA products were analyzed with immunoblotting. (b) Chromatin 
immunoprecipitation (ChIP) analysis was performed using cells cultured in GM (open bars) or AIM (filled 
bars) for 12 h with anti-TonEBP serum (TonEBP) or normal serum (N.S.). Precipitated DNA samples were 
analyzed by q-PCR with primer pairs for various regions of the PPARγ 2 promoter indicated at the bottom. 
Mean + SD, n = 3. *p < 0.05. (c) Cells transfected with scrambled or TonEBP-targeted siRNA in GM were 
switched to AIM for up to 48 h, as indicated. Nuclei were prepared, and half of them were treated with 
micrococcal nuclease while the other half was treated without the enzyme. Genomic DNA was isolated and 
analyzed by q-PCR using primer pairs covering -360/-155 of the PPARγ 2 promoter, and -273/-203 of the 
GAPDH promoter. Chromatin accessibility was calculated from (amount of PCR product in undigested 
sample) / (amount of PCR produce in digested sample). Error bars representing SD are not shown because 
they are smaller than the marks representing means (n = 3). (d) Cells were transfected with siRNA’s as 
indicated in GM. The cells were then cultured for 12 h in GM or AIM followed by ChIP analyses using anti-
H3K9me2 and anti-C/EBPβ antibodies. Precipitated DNA samples were analyzed by q-PCR with primers 
covering -360/-155 region of the PPARγ 2 promoter. Mean + SD, n = 3. *p < 0.05.
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a chemokine for immune cell infiltration to adipose tissues, also reduced dramatically (Fig. 6b). TonEBP 
deficiency is expected to lessen inflammation in the adipose tissues due to the combined effects of ele-
vated adiponectin and suppressed pro-inflammatory cytokines and chemokines.
Discussion
Given the pro-inflammatory actions of TonEBP in settings of rheumatoid arthritis12 and atherosclero-
sis13, our motivation of this study was to investigate the role of TonEBP in obesity and insulin resistance 
because inflammation is critically involved32–34. As a first step in this direction, we focused on adipocytes 
Figure 5. TonEBP deficiency stimulates the PPARγ2 promoter in a C/EBP-dependent manner. (a) 
Schematic representation of the PPARγ 2 promoter fragments cloned from mouse genomic DNA. Each of 
them was cloned in pGL3 to create a luciferase reporter. (b to e) 3T3-L1 cells transfected with scrambled 
(Scr, open bars) or TonEBP-targeted siRNA (filled bars) were cultured for 2 days in AIM. Then, they were 
transfected with increasing amounts of the 3 kb promoter reporter (b) or promoter-less pGL3 or each of 
the 3 promoters (c). In (d), a C/EBP-reporter construct (CRE) or pGL3 was transfected. In (e ), the 0.5 kb 
promoter construct was mutated to remove CEBP binding sites to create ‘CEBP mut,’ as described in 
Methods. Luciferase activity is shown in Mean + SD, n = 4. *p < 0.05.
www.nature.com/scientificreports/
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and adipogenesis. To our surprise, we find that TonEBP suppresses PPARγ 2 expression by binding to the 
proximal region of the PPARγ 2 promoter. This binding is associated with di-methylation of the lysine 
9 in Histone H3 and limited chromatin access. In response to adipogenic signals, TonEBP dissociates 
from the promoter leading to opening of the locus in association with reduced Histone H3 methylation 
and recruitment of C/EBPβ. Reduced TonEBP expression results in a profound enhancement of PPARγ 2 
expression leading to increased adipogenesis and insulin signaling.
Our data also demonstrate that TonEBP promotes adipose inflammation as indicated by higher adi-
ponectin expression in combination with lower pro-inflammatory genes in response to TonEBP deficiency. 
Thus, under conditions of TonEBP deficiency adipogenesis is promoted despite reduced inflammation. 
This may not necessarily contradict the requirement of adipose inflammation for adipogenesis17 per-
haps because sufficient level of inflammation was maintained in TonEBP deficient conditions: Except for 
MCP-1, most of pro-inflammatory genes displayed moderate suppression by TonEBP deficiency.
In view of the role of inflammation in adipose insulin resistance18–23,32–34, the actions of TonEBP 
seem puzzling: While TonEBP promoted inflammation, it suppressed insulin sensitivity in adipocytes. 
Disconnect between obesity and insulin resistance has been observed in patients35,36. For example, about 
one in four obese individuals are metabolically healthy as judged by insulin resistance and systemic 
inflammation37. Individual variations in the level of TonEBP expression can potentially contribute to 
such disconnect. One can envision an obese individual with low level of TonEBP expression. This indi-
vidual might have healthy insulin sensitivity despite the obesity. We reported previously that diabetic 
nephropathy is associated with ~50% higher TonEBP expression among patients with type 1 diabetes38 
demonstrating that there are substantial and meaningful individual variations in the level of TonEBP 
expression. In this regard, we are intrigued by the improved adipocyte insulin sensitivity in animals with 
TonEBP haploindeficiency. This observation raises the possibility that variations in TonEBP expression 
level lead to individual variations in adipose tissue insulin sensitivity and may contribute to disconnect 
between obesity and insulin resistance in certain individuals.
As discussed above, deficiency of TonEBP due to siRNA-mediated knockdown or mutant TonEBP 
allele elevates PPARγ expression and improves insulin signaling in combination with reduced inflam-
mation. As such, TonEBP deficiency mimics many aspects of synthetic PPARγ activators such as thi-
azolidinediones39–43. TonEBP provides an attractive therapeutic target for insulin resistance in lieu of 
thiazolidinediones.
Methods
Cell culture and transfection. 3T3-L1 pre-adipocytes cell line from American Type Culture 
Collection (ATCC) were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Hyclone, Logan, 
UT, USA) supplemented with 10% Bovine Calf Serum (BCS, Gibco-BRL, Gaithersburg, MD, USA) with 
penicillin-streptomycin (Hyclone). When the cells grow at the 70% of confluence, cells were transfected 
with TonEBP siRNA or control scrambled siRNA using lipofectamine RNAiMAX (Invitrogen, Carlsbad, 
CA, USA) following the manufacturer’s instructions. For induction of adipocyte differentiation, AIM 
Figure 6. TonEBP stimulates adiponectin expression but suppresses pro-inflammatory cytokines. (a) 
3T3-L1 transfected with scrambled (open bars) or TonEBP-targeted siRNA (filled bars) were cultured for 6 
days in AIM. Quantitative RT-PCR was performed form mRNA’s shown. (b) MCP-1 mRNA and MCP-1 in 
the culture media were measured. Mean + SD, n = 4. *p < 0.05 vs. corresponding scrambled siRNA.
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including 1 μ M dexamethasone, 0.5 mM isobutylmethylxanthine, and 1 μ M insulin (MDI) in DMEM 
supplemented with 10% Fetal Bovine Serum (FBS, Gibco-BRL) was used as described44. Human bone 
marrow derived mesenchymal stem cell (hBMSC) purchased from Cambrex /Lonza (Walkersville, MD, 
USA) were maintained in DMEM supplemented with 10% FBS. At the 90% of confluence, cells were 
transfected with same procedure as 3T3-L1. Adipocyte differentiation was induced by AIM with indo-
methacin (100 μ M) as described45. For adenoviral overexpression, 3T3-L1 cells were infected with ade-
novirus expressing TonEBP or β -galactosidase at the 70% of confluence before switching to AIM.
Mice. All the methods involving live mice were carried out in accordance with the approved guide-
lines. All experimental protocols were approved by Institutional Animal Care and Use Committee of the 
Ulsan National Institute of Science and Technology (UNISTACUC-12-15-A).
Stromal vascular fraction (SVF) isolation. SVF’s were isolated from 6-week-old male TonEBP+/Δ 
mice and their TonEBP+/+ littermates. Subcutaneous fat pads were dissected and minced in Krebs-Ringer 
buffer supplemented with HEPES (pH7.4), 2% bovine serum albumin, 5 mM D-glucose, 100 mM aden-
osine, and 2 mg/ml type II collagenase. They were incubated at 37 ˚ C with gentle shaking at 100 rpm for 
45 min. After centrifugation at 500 g for 10 min, pellets were resuspended and incubated with RBC lysis 
buffer (ACK lysing buffer, Gibco-BRL) for 10 min. After filtration through a 70 μ m filter, the cells were 
cultured for 2 days in complete DMEM/F12 (Lonza Walkersville, MD). Adipogenesis was induced in a 
modified AIM containing insulin (10 μ g/ml), dexamethasone (1 μ M), IBMX (0.5 mM), Indomethacin 
(125 μ M), T3 (1 nM), and rosiglitazone (1 μ M) for 2 days, followed by 3 days in DMEM/F12 supple-
mented with insulin (10 μ g/ml) and T3 (1 nM).
Western blot analysis and nuclear fraction extraction. Cells were washed with PBS and lysed 
in 10 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, protease inhibitor, 
1 mM sodium orthovanadate, and phosphatase inhibitor cocktail for 30 min at 4 ˚ C. Isolated cell extracts 
were separated on SDS-PAGE and transferred to nitrocellulose membrane (Whatman, Clifton, NJ, USA). 
After blocking nonspecific binding sites with 5% nonfat milk at RT for 1 hr, membranes were incubated 
with primary antibodies overnight at 4 ˚ C. Antibodies to C/EBPα , C/EBPβ , PPARγ , FABP4, Perilipin, 
p-AKT(Ser473), and AKT were obtained from Cell Signaling Technologies (Berkeley, CA, USA) and 
antibodies to Hsc70 were obtained from Rockland (Gilbertsville, PA, USA).The immune complexes were 
detected with horseradish peroxidase-conjugated secondary antibodies. Protein detection was performed 
by using enhanced chemiluminescence (Pierce, Rockford, IL, USA). Nuclear fraction was extracted using 
a nuclear extract kit (Pierce) according to the manufacturer’s recommendation.
Oil-Red-O staining. Differentiated adipocytes are washed by PBS, fixed with 4% paraformaldehyde 
for 1 hour, washed with PBS, and then stained with 0.6% Oil red O dye in isopropanol and water (6:4) 
for 1 hour at 4 ˚ C followed by washing with PBS. Then, the stained cells were de-stained with isopropanol 
and optical density was measured by spectrometry at 500 nm wavelength. Optical density of each sample 
was normalized by that of scrambled siRNA-transfected cell cultured in growth medium.
qRT-PCR analysis. Total RNA was isolated using Trizol reagent (Invitrogen). Reverse transcrip-
tion was performed with 4μ g of total RNA, and resultant cDNA were subjected to quantitative time 
PCR for TonEBP, C/EBPβ , C/EBPα , PPARγ 1/2, FABP4, SREBP-1c, SCD1, ACC, adiponectin, and 
pro-inflammatory genes and a loading control, 36B4. Primers used are described in supplementary table 
S1.
Isolation of primary adipocytes. Primary adipocytes were isolated from 3-month-old male animals 
as described46. Briefly, epididymal fat pads were minced in Krebs-Ringer buffer (5 ml/g tissue) supple-
mented with 25 mM HEPES (pH7.4), 2% bovine serum albumin, 5 mM D-glucose, 100 mM adenosine, 
and 2 mg/ml type II collagenase. They were incubated at 37 ˚ C with gentle shaking at 100 rpm for 45 min. 
After centrifugation at 500 rpm for 30 sec, adipocyte fraction was separated. Adipocytes were incubated 
with Krebs-Ringer-HEPES buffer supplemented with 50 nM insulin for 10 min with gentle shaking before 
immunoblot analyses.
Glucose uptake assay and Insulin signaling. Glucose uptake rate was measured as described47. 
Briefly, cells were serum started for 2 h before they were incubated for 30 min in low glucose DMEM 
containing 20 μ M 6-NBDG without or with 100 nM insulin. The cells were lysed and fluorescence was 
measured using λ ex = 466 nm and λ em = 540 nm. To assess insulin signaling, cells were starved for 18 h, 
and then, incubated for 30 min without or with 100 nM insulin. The cells were immunoblotted for AKT 
and p-AKT, as described above.
Promoter and Reporter assay. Mouse PPARγ 2 promoter fragments (Fig.  5a) were inserted 
into pGL3 (Promega, Madison, WI, USA). C/EBP binding site in 0.5 kb PPARγ 2 promoter con-
struct was mutated using the following primer - AGT(GCA)ATTTTAAAAAAA(GC)AAT (wild 
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type sequence in parenthesis). At the 2 day after differentiation, cells were transfected for 6 hours 
with PPARγ 2-pGL3 and renilla luciferase plasmids. After 24 hours of post-induction using DMEM 
with insulin (1 μ M), luciferase activity was measured. 3x PPAR-luc reporter, PPAR responsive ele-
ment (PPRE), were from J.B. Kim48. At the 4 days after differentiation, cells were transfected with 
PPRE reporter plasmid and renilla luciferase plasmids. After post-inducing adipogenesis using 
DMEM with insulin (1 μ M), luciferase activity was measured. Three CEBP responsive elements (CRE, 
underlined below) reporter plasmid was produced by cloning double stranded CRE oligonucleo-
tide (AGATCTGTTGCGCAAGTGGAGGTTGCGCAAGTGGCAGGTTGCGCAAGCTCGAG) into 
pGL3-basic as described49. CRE reporter plasmid was transfected after 2 day of adipogenic induction. 
After 6 hours, additional adipogenic induction was done by MDI cocktails. 24 hours after additional 
induction of adipogenesis, luciferase reporter activity was measured.
DNA affinity precipitation assay (DAPA). Cells were washed with PBS and lysed in 20 mM Tris, 
pH 7.5, 150 mM NaCl, 1% Triton X-100, protease inhibitor, 1 mM sodium orthovanadate, and phos-
phatase inhibitor cocktail for 30 min at 4 ˚ C. 0.5 mg/ml of protein was incubated with 30 nM biotinylated 
oligonucleotide probe overnight at 4 °C in 7.2 mM Tris [pH7.5], 16 mM HEPES [pH 7.5], 4% glycerol, 
166 mM NaCl, 0.4 mM EDTA, 0.8 mM MgCl2, and 0.28% Triton X-100. Protein-DNA complexes were 
isolated using pre-cleared streptavidin-agarose bead and analyzed by western blotting
Chromatin accessibility assay by qPCR. Chromatin accessibility assay by q-PCR was performed 
using MNase described as previously with minor modification50. Washed cells were lysed in cold NP-40 
lysis buffer (10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl2, 0.5% NP-40, 0.15 mM spermine 
(Sigma-Aldrich, St. Louis, MO, USA), 0.5 mM spermidine(Sigma-Aldrich), followed by incubation on 
ice for 5 min. Nuclei were pelleted by centrifuge at 5000 rpm for 3 min at 4 ˚ C and resuspended with 
MNase digestion buffer without CaCl2 (10 mM Tris-HCl (pH 7.4), 15 mM NaCl, 60 mM KCl, 0.15 mM 
spermine, 0.5 mM spermidine). After centrifugation, the nuclei were resuspended with MNase digestion 
buffer supplemented with CaCl2. Then, half of the each sample was treated MNase with 5 unit/sample 
and the other half of that was treated digestion buffer, and samples were incubated at 37 ˚ C for 1 min. 
The digestion reaction was stopped by addition of stop solution (100 mM EDTA/10 mM EGTA (pH 8.1) 
in 10 mM Tris-HCl (pH 7.4)). RNaseA (10 μ g/sample) and proteinase K (100 μ g/sample) were added 
and samples were incubated at 37 ˚ C overnight. DNA, purified by Phenol/chloroform/isoamyl alcohol 
extraction, was analyzed by q-PCR using primer pairs covering -360/-155 of the PPARγ 2 promoter, and 
-273/-203 of the GAPDH promoter. Chromatin accessibility was calculated as described in Fig. 4 legend.
Chromatin immunoprecipitation (ChIP). ChIP was performed using a commercial kit (Millipore, 
Bedford, MA, USA). In brief, cells were crosslinked with 1% formaldehyde followed by addition of 
125 mM glycine. After washing, cells were sonicated and immunoprecipitated with normal serum, 
anti-TonEBP, anti-H3K9me2 (Abcam, Cambridge, MA, USA), and anti-C/EBPβ (Abcam) antibodies at 
4 ˚ C overnight. After elution and reverse crosslinking the antibody/DNA complexes, DNA was purified 
by DNA purification kit (Qiagen, Hilden, Germany) and analyzed by q-PCR using primer pairs covering 
specific region of the PPARγ 2 promoter in duplicates. Primer pairs for q-PCR covered -360/-155 of the 
PPARγ 2 promoter. Data was shown as amount of DNA relative to input.
Statistical analysis. Data are presented as means + SD. Differences between groups were analyzed 
by student’s t-test, and statistically significance was considered at *p < 0.05.
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